NFKB1 and amyotrophic lateral sclerosis: As an example of the complex consequences of this phenomenon, we present the challenges of modulating nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) (a transcription factor that acts as a master regulator of neuroinflammation) as a therapeutic target for ALS.